Enanta Pharmaceuticals (ENTA) Profit After Tax (2012 - 2026)
Enanta Pharmaceuticals (ENTA) posted Profit After Tax of -$13.1 million for Q1 2026, down 9.66% on a QoQ basis from -$11.9 million in Q4 2025, and up 42.19% year-over-year from -$9.2 million in Q1 2025.
Enanta Pharmaceuticals (ENTA) Profit After Tax (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals' Profit After Tax history runs 15 years deep, the most recent figure standing at -$13.1 million for Q1 2026.
- Quarterly Profit After Tax rose 42.19% year-over-year to -$13.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$62.0 million (up 35.71% YoY) and the FY2025 annual result came in at -$81.9 million, up 29.43% from the prior year.
- Profit After Tax was -$13.1 million for Q1 2026 at Enanta Pharmaceuticals, down from -$11.9 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$11.9 million in Q4 2025 and bottomed at -$39.1 million in Q2 2023.
- A 5-year average of -$26.4 million and a median of -$28.1 million in 2023 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2022 — Profit After Tax plunged 52.38% — and 2025, when it soared 46.44%.
- Enanta Pharmaceuticals' Profit After Tax stood at -$29.0 million in 2022, then dropped by 15.25% to -$33.4 million in 2023, then jumped by 33.28% to -$22.3 million in 2024, then jumped by 46.44% to -$11.9 million in 2025, then declined by 9.66% to -$13.1 million in 2026.
- Business Quant data shows ENTA's Profit After Tax at -$13.1 million in Q1 2026, -$11.9 million in Q4 2025, and -$18.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Enanta Pharmaceuticals | 376.07 Mn | 212.29 Mn | - | -13.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.09 Mn |
| Dec 31, 2025 | -11.94 Mn |
| Sep 30, 2025 | -18.70 Mn |
| Jun 30, 2025 | -18.26 Mn |
| Mar 31, 2025 | -22.64 Mn |
| Dec 31, 2024 | -22.29 Mn |
| Sep 30, 2024 | -28.82 Mn |
| Jun 30, 2024 | -22.66 Mn |
| Mar 31, 2024 | -31.16 Mn |
| Dec 31, 2023 | -33.41 Mn |
| Sep 30, 2023 | -28.11 Mn |
| Jun 30, 2023 | -39.07 Mn |
| Mar 31, 2023 | -37.66 Mn |
| Dec 31, 2022 | -28.99 Mn |
| Sep 30, 2022 | -26.35 Mn |
| Jun 30, 2022 | -31.70 Mn |
| Mar 31, 2022 | -33.59 Mn |
| Dec 31, 2021 | -30.12 Mn |
| Sep 30, 2021 | -24.60 Mn |
| Jun 30, 2021 | -24.02 Mn |